Genomics and risk modeling firm MyOme has announced a significant enhancement to its leadership by appointing Sam Roosz and Dr. Ravi Thadhani to its Board of Directors. This strategic move brings together profound expertise in healthcare technology, data ecosystems, clinical operations, and regulatory affairs. The appointments are set to fortify MyOme's position as it continues to expand its advanced AI-powered, whole-genome healthcare platform for broader clinical and research applications.
Strategic Leadership for Growth and Innovation
The addition of these two distinguished executives is a calculated step to accelerate the company's mission of integrating genomic intelligence into mainstream medicine. Matt Rabinowitz, Co-Founder and Executive Chairman of MyOme, noted their combined expertise will be invaluable as the company grows. He highlighted Roosz's success in scaling health-data platforms and Thadhani's experience guiding diagnostics through complex FDA pathways as critical assets for the company's future.
MyOme's platform utilizes sophisticated artificial intelligence and integrated risk modeling to provide actionable genomic insights across a wide range of health areas. The company focuses on cardiometabolic, liver, kidney, and cognitive diseases, as well as oncology and rare conditions. Its goal is to improve patient outcomes and lower healthcare costs by enabling earlier disease detection and preventative action through comprehensive genetic analysis.
Expertise in Health Data and Technology
Sam Roosz brings a wealth of experience in building and scaling influential health technology ventures. As the Co-Founder and CEO of Crescendo Health, he is developing a patient-centric platform for medical research data contribution. His previous role as a co-founder at Datavant involved creating the nation's largest health data ecosystem, which will directly inform MyOme's expansion strategy across various health networks.
Roosz expressed his enthusiasm for MyOme's work in making whole-genome analysis clinically valuable and actionable for both patients and their healthcare providers. He believes that delivering validated genomic insights at a population scale holds the potential to fundamentally reshape the delivery of healthcare. He looks forward to supporting the company as it enters its next significant phase of growth and market penetration.
Distinguished Clinical and Regulatory Acumen
Dr. Ravi Thadhani is a nationally recognized leader with over three decades of experience in academic medicine, clinical investigation, and healthcare leadership. In his current capacity as Executive Vice President of Clinical Affairs and Chief Medical Officer at Cedars-Sinai, he oversees critical clinical functions. His prior leadership roles at Emory University, Harvard Medical School, and Mass General Brigham underscore his deep industry knowledge.
Dr. Thadhani's extensive regulatory experience, including service on the FDA's Cardiovascular and Renal Drugs Advisory Board, aligns perfectly with MyOme's commercialization strategy. His firsthand involvement in guiding diagnostics through FDA approval pathways and overseeing data safety for clinical trials provides a crucial perspective. This background will be instrumental in advancing MyOme's evidence-building and regulatory efforts for its innovative diagnostic tools.
According to Dr. Thadhani, insights powered by whole-genome analysis represent one of the most significant opportunities to transform how diseases are understood and managed. He praised MyOme's integrated approach, which combines monogenic and polygenic data with robust clinical evidence and regulatory discipline. He is confident this positions the company to make a substantial impact across the entire healthcare system.
The appointments of Sam Roosz and Dr. Ravi Thadhani mark a pivotal moment for MyOme, signaling a clear focus on strategic scaling and clinical validation. By integrating top-tier expertise in data technology and regulatory science, the company is reinforcing its foundation for future growth. This move strongly positions MyOme to lead the charge in making comprehensive genomic intelligence a fundamental component of modern preventative medicine.